Syringin (Phenylpropanoid Glycoside)

Syringin is a phenylpropanoid glycoside found in lilac bark and other plants that demonstrates cardioprotective and anti-inflammatory properties. Research shows it protects heart tissue by modulating oxidative stress pathways and reduces inflammatory responses through inhibition of macrophage activation.

Origin & History

Syringin is a phenylpropanoid glycoside (4-O-β-D-glucopyranosyl-syringol) primarily sourced from plants in the genus Lilium (lily bulbs) and other species like Acer and Strychnos used in traditional Chinese medicine. It is extracted through methanol or ethanol solvent extraction followed by chromatographic separation including silica gel column chromatography and HPLC for purification.

Historical & Cultural Context

Syringin-containing plants like Lilium brownii (hundred-union lily bulb) have been used in traditional Chinese medicine for centuries to treat conditions such as adjuvant arthritis, cardiac issues, and inflammation, typically prepared as decoctions or extracts. Historical records document anti-arthritic effects in rat models mimicking TCM applications (PMID: 21351587).

Health Benefits

• May protect heart tissue from ischemia/reperfusion injury by reducing infarct size and improving cardiac function (preclinical evidence only, rat models)
• Could help manage inflammatory arthritis by inhibiting macrophage-synoviocyte crosstalk and reducing M1 polarization (preclinical evidence only, rat CIA models)
• May support blood glucose regulation in type 2 diabetes through alpha-linolenic acid metabolism modulation (preclinical evidence only, mouse models)
• Potentially reduces inflammatory markers including TNF-α, IL-1β, and IL-6 through NRF2/HO-1 activation (preclinical evidence only)
• May provide antioxidant protection by upregulating SOD and catalase enzymes (preclinical evidence only)

How It Works

Syringin protects cardiac tissue by reducing oxidative stress and improving mitochondrial function during ischemia-reperfusion injury. It inhibits inflammatory responses by preventing M1 macrophage polarization and blocking pro-inflammatory cytokine production. The compound also modulates NF-κB and MAPK signaling pathways to reduce tissue damage and inflammation.

Scientific Research

No human clinical trials, RCTs, or meta-analyses have been conducted on syringin. All available evidence comes from preclinical animal studies including rat myocardial ischemia/reperfusion models (PMID: 36840496), collagen-induced arthritis rat models (PMID: 39842374), and high-fat diet/STZ-induced diabetes mouse models (PMID: 41125012).

Clinical Summary

Current evidence for syringin is limited to preclinical animal studies, primarily in rat models. Cardiovascular studies show significant reduction in myocardial infarct size and improved cardiac function parameters during ischemia-reperfusion protocols. Anti-inflammatory research demonstrates reduced joint inflammation and macrophage infiltration in arthritis models. No human clinical trials have been conducted to date, making safety and efficacy in humans unknown.

Nutritional Profile

Syringin (also known as eleutheroside B; CAS 118-34-3) is a phenylpropanoid glycoside, not a macronutrient or food source itself, but a discrete phytochemical compound with molecular formula C17H24O9 and molecular weight of 372.37 g/mol. It is not a source of protein, fat, dietary fiber, vitamins, or minerals in any nutritional sense. Structurally, it consists of sinapyl alcohol (a phenylpropanoid aglycone) linked to a glucose moiety via a beta-glycosidic bond. It is found in concentrated form in the bark and root bark of Syringa vulgaris (common lilac), Eleutherococcus senticosus (Siberian ginseng, where it comprises approximately 0.6–1.0% of dry root extract), Ilex pubescens, and select species of Fraxinus and Magnolia. In standardized Eleutherococcus extracts, syringin content typically ranges from 0.5 mg/g to 6 mg/g of dry extract depending on plant part and preparation method. Bioavailability: Oral bioavailability is limited by intestinal hydrolysis; gut microbiota cleave the beta-glycosidic bond to release sinapyl alcohol, which undergoes further hepatic phase II conjugation (glucuronidation, sulfation). Peak plasma concentrations in rodent studies occur at approximately 30–60 minutes post-oral administration. Lipophilicity is low (estimated LogP ≈ -0.5 to 0.2), favoring aqueous solubility (~2–5 mg/mL in water at 25°C) but potentially limiting passive membrane permeability. No caloric value is assigned as a pure compound; it is used exclusively as a bioactive phytochemical at doses studied in the range of 10–100 mg/kg body weight in preclinical models.

Preparation & Dosage

No clinically studied human dosages are available. Animal studies used intraperitoneal administration without specified mg/kg ranges in published abstracts. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Phillygenin, quercetin, resveratrol, curcumin, alpha-lipoic acid

Safety & Interactions

Safety data for syringin in humans is not available due to lack of clinical trials. Potential interactions with cardiovascular medications or anti-inflammatory drugs are unknown and should be considered given its mechanisms of action. Pregnancy and breastfeeding safety has not been established. Individuals with cardiovascular conditions or those taking blood pressure medications should exercise caution until human safety data becomes available.